Monsanto unaffected by merger halt?

Article Abstract:

Monsanto has announced that it plans to raise $4 billion. To this end, the company, which once planned to merge with American Home Products (AHP), plans to issue about $2.5 billion through long-term unsecured debt and $1 billion in divestitures. The latter move will most likely cost about 1,400 Monsanto employees their jobs. The company will undertake this financial plan in order to pay for its acquisitions of Dekalb Genetics, Delta & Pine Land, and Cargill Seeds. Observers believe that although Monsanto has not greatly harmed by not following through with the AHP merger, it would nonetheless have benefited from AHP's finances.

Financial management, Chemicals & Allied Products, Chemical Manufacturing, Chemicals, Monsanto Co., MTC

---

California votes for embryonic stem cell research

Article Abstract:

The Californian voters, on 2 November 2004, strongly supported the state proposition 71, which was related to the embryonic stem cell research. This measure will authorize an annual spending of nearly $300 million through tax-free bond measures, which will facilitate embryonic stem cell research and provide the researchers with a new means for overcoming the hurdles caused by federal bottlenecks.

Government expenditures, California, Political aspects, Elections, Embryology, Experimental, Embryological research, Stem cells, Government finance, Embryonic stem cells

---

FDA panel recommends easing gene therapy trial limits

Article Abstract:

Food and Drug Administration (FDA) officials would soon permit many of those recently halted trails to resume, albeit with stronger safety measures than before. Biological Response Modifiers Advisory Committee (BRMAC) adviced the FDA regarding the broader gamut of gene transfers clinical trials that rely on retroviral vectors.

Methods, Clinical trials, Gene therapy, United States. Food and Drug Administration, Genetic transformation

Similar abstracts:

• Abstracts: WMD detection gear at ports falls short: GAO. Danish bio-terror research
• Abstracts: Human responses to augmented virtual scaffolding models. Preventing falls from roofs: a critical review. Sizing and fit of fall-protection harnesses
• Abstracts: Reverse mergers attract top-tier biotechs in sluggish IPO market. More biotechs gamble on convertibles
• Abstracts: Scripps lured to Sunshine State. Companies jostle for access to public markets. Increasing number of companies found ineligible for SBIR funding
• Abstracts: Canada's bumper biotech budget. Angel investors shy away from biotech

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.